首页> 美国政府科技报告 >Final Phase II Report of Task I Preclinical Intravenous Toxicity Study of N-Methylformamide (NSC 3051) in CD2F1 Mice and Beagle Dogs
【24h】

Final Phase II Report of Task I Preclinical Intravenous Toxicity Study of N-Methylformamide (NSC 3051) in CD2F1 Mice and Beagle Dogs

机译:任务I最终第二阶段报告N-methylformamide(NsC 3051)在CD2F1小鼠和Beagle犬中的临床前静脉毒性研究

获取原文

摘要

In CD2F1 mice administered a single intravenous dose of N-methylformamide (NSC 3051) the day 29 LD10, LD50, and LD90 for combined sexes are 1167.73, 2308.53, and 4563.86 mg/kg (3503.19, 6925.59, and 13691.58 mg/sq. m). The combined sexes estimate for mice administered five consecutive daily doses are 441.22, 1336.85, and 4050.47 mg/kg/day (1323.66, 4010.55, and 12151.41 mg/sq. m/day). Male mice were more susceptible to the lethal effects of N-methylformamide in both studies.

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号